Michigan Researchers ID Potential Glycoprotein Biomarker for Pancreatic Cancer
May 06, 2011
Michigan Researchers ID Potential Glycoprotein Biomarker for Pancreatic Cancer
Researchers at the University of Michigan Comprehensive Cancer Center demonstrated that a mass spectrometric blood serum assay based on haptoglobin fucosylation patterns could become an accurate method for pancreatic cancer diagnosis.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Lung Cancer Study Highlights Current Limitations of MALDI Mass Spec
July 22, 2011 / ProteoMonitor - NCI's Early Detection Research Network Running Trials to Compare Biomarker-Based Cancer Diagnostics
April 22, 2011 / ProteoMonitor - Celera's Proteomics Program Focuses on Biomarker-Based Lung Cancer Test
April 15, 2011 / ProteoMonitor - Glycomics Firm Sialix Developing Auto Antibody-Based Tests for Breast, Colon, Prostate Cancers
April 29, 2011 / ProteoMonitor - ASU Biodesign Scientists Hope to Apply Direct-to-Consumer Model to Proteomics Testing
February 4, 2011 / ProteoMonitor